Cabozantinib is also a multitarget small molecule tyrosine kinase inhibitor (TKI) that inhibits mesenchymal‐epithelial transition (MET), VEGFR, ROS proto‐oncogene 1 (ROS1), AXL receptor tyrosine kinase (AXL), neurotrophic tyrosine receptor kinase (NTRK), KIT, RET, and was approved by the US FDA in 2019 for advanced HCC [530]. Here, KDR is linked to hepatocellular carcinoma.